ストックスクリーナーアプリを入手
1.40
7.69%
0.10
アフターアワーズ：
1.42
0.02
+1.43%
前日終値:
$1.30
開ける：
$1.31
24時間の取引高:
459.98K
Relative Volume:
0.26
時価総額：
$46.64M
収益：
$3.04M
当期純損益:
$-33.97M
株価収益率:
-1.0145
EPS:
-1.38
ネットキャッシュフロー:
$-52.47M
1週間 パフォーマンス:
-15.66%
1か月 パフォーマンス:
-31.71%
6か月 パフォーマンス:
-65.00%
1年 パフォーマンス:
-55.13%
1日の値動き範囲:
$1.30
$1.415
1週間の範囲:
$1.30
$1.72
52週間の値動き範囲:
$1.30
$8.75
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
名前
Rani Therapeutics Holdings Inc
セクター
電話
(408) 457-3700
住所
2051 RINGWOOD AVENUE, SAN JOSE
RANI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
1.40 | 46.64M | 3.04M | -33.97M | -52.47M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-02 | 開始されました | Oppenheimer | Outperform |
| 2024-06-14 | 開始されました | Maxim Group | Buy |
| 2024-06-13 | 開始されました | Rodman & Renshaw | Buy |
| 2023-04-17 | 再開されました | BTIG Research | Buy |
| 2022-10-11 | 開始されました | UBS | Buy |
| 2022-07-27 | 開始されました | H.C. Wainwright | Buy |
| 2022-06-13 | 開始されました | Wedbush | Outperform |
すべてを表示
Rani Therapeutics Holdings Inc (RANI) 最新ニュース
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $11.71 Average PT from Brokerages - MarketBeat
Rani Therapeutics stock hits 52-week low at $1.32 - Investing.com
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Insider Kate Mckinley Acquires 17,960 Shares - MarketBeat
Rani Therapeutics stock hits 52-week low at $1.85 By Investing.com - Investing.com Nigeria
Rani Therapeutics stock hits 52-week low at $1.85 - Investing.com India
Rani Therapeutics stock hits 52-week low at $1.94 By Investing.com - Investing.com Nigeria
Rani Therapeutics stock hits 52-week low at $1.94 - Investing.com India
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $11.71 Average Target Price from Analysts - Defense World
Brokerages Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Price Target at $11.71 - MarketBeat
What is Zacks Small Cap’s Forecast for RANI FY2024 Earnings? - Defense World
What is Zacks Small Cap's Forecast for RANI FY2024 Earnings? - MarketBeat
RANI: Third Quarter Update - MSN
Rani Therapeutics' (RANI) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Rani Therapeutics Advances in Biotherapeutics Market - TipRanks
Rani Therapeutics Holdings Inc (RANI) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires New Stake in Rani Therapeutics H - GuruFocus.com
Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update - The Manila Times
Rani Therapeutics Slashes Q3 Loss by 31%, Secures $20M Funding for GLP-1 Development | RANI Stock News - StockTitan
Rani Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Brokerages Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) PT at $11.71 - Defense World
Analysts Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Target Price at $11.71 - MarketBeat
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Sees Significant Growth in Short Interest - MarketBeat
Allied Gaming & Entertainment And 2 Other US Penny Stocks To Watch - Simply Wall St
RANI: New Triagonist Data in Weight Loss - Zacks Small Cap Research
Rani Therapeutics shares hold buy rating on positive preclinical data By Investing.com - Investing.com Australia
Rani Therapeutics stock gets positive outlook from H.C. Wainwright after novel obesity candidate progress - Investing.com Australia
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.75% - MSN
Rani Therapeutics shares hold buy rating on positive preclinical data - Investing.com
Rani Therapeutics (NASDAQ:RANI) Receives "Buy" Rating from HC Wainwright - MarketBeat
Rani Therapeutics reports promising obesity treatment delivery By Investing.com - Investing.com South Africa
Rani therapeutics sees $10 million in stock sales by major investors By Investing.com - Investing.com
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Major Shareholder South Cone Investments Limited Sells 3,829,360 Shares - MarketBeat
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.75% - MSN
Rani Therapeutics reports promising obesity treatment delivery - Investing.com
Rani Therapeutics Announces New Preclinical Pharmacokinetic - GlobeNewswire
Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist - The Manila Times
Rani Therapeutics (RANI) Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist - StreetInsider.com
Rani Therapeutics to sell 3M shares at $3.00 in registered direct offering - MSN
Recent Insider Activity Could Benefit Comcast Corp (CMCSA) - Knox Daily
Market Momentum: Rani Therapeutics Holdings Inc (RANI) Registers a -33.33 Decrease, Closing at 2.12 - The Dwinnex
There is no doubt that Rani Therapeutics Holdings Inc (RANI) ticks all the boxes. - SETE News
An Analysis of Avidity Biosciences Inc (RNA)’s Potential Price Growth - Knox Daily
Form 424B5 Rani Therapeutics Holdin - StreetInsider.com
Rani Therapeutics Holdings Inc (RANI) 財務データ
収益
当期純利益
現金流量
EPS
Rani Therapeutics Holdings Inc (RANI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Imran Talat | Chief Executive Officer |
Dec 09 '24 |
Buy |
1.94 |
10,296 |
19,974 |
494,751 |
| South Cone Investments Limited | 10% Owner |
Oct 15 '24 |
Sale |
2.65 |
3,829,360 |
10,141,674 |
8,302,194 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):